Publications (4)5.86 Total impact
[show abstract] [hide abstract]
ABSTRACT: A 23-year-old woman was suffered from ruptured ovarian endometrioma with an elevated CA125 and CA19-9 concentration; 9537 and 15,653IU/ml, respectively. Rapid decrease in serum CA125 and CA19-9 was recognized before surgery. Such high levels of both antigens have not been reported in a patient with endometriosis.European Journal of Obstetrics & Gynecology and Reproductive Biology 11/2002; 105(1):75-6. · 1.97 Impact Factor
Article: Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cisplatin chemotherapy.[show abstract] [hide abstract]
ABSTRACT: Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cisplatin therapy is a previously unreported complication. A 63-year-old woman with stage Ib2 squamous cell carcinoma of the cervix was treated with intraarterial cisplatin infusion in a neoadjuvant setting. Four days following the second course of chemotherapy, she became drowsy with severe fatigue and decreased mental awareness. Blood tests showed sodium of 110 mEq/L. Urine and plasma osmolarities were 308 and 240 mOsm/kg, respectively, confirming the diagnosis of a syndrome of inappropriate secretion of antidiuretic hormone induced by intra-arterial cisplatin infusion. The potential for development of clinically significant hyponatremia early in the course of cisplatin therapy with any infusion routes emphasizes the need to closely monitor patients.Gynecologic Oncology 11/2002; 87(1):150-1. · 3.89 Impact Factor
Article: Neoadjuvant Chemotherapy Using Low-Dose Consecutive Intraarterial Infusions of Cisplatin Combined with 5-Fluorouracil for Locally Advanced Cervical Adenocarcinoma[show abstract] [hide abstract]
ABSTRACT: Objective. The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma.Methods. Eleven patients were treated with preoperative neoadjuvant chemotherapy. Those eligible included patients with previously untreated stage IB, II, or III adenocarcinoma with good performance status. Treatment consisted of bilateral internal iliac artery infusion of cisplatin (a total of 10 mg/day) for 30 min, followed by 5-FU (a total of 250 mg/day) given by 24-hour continuous infusion for 10 days. Treatment was repeated every 3 weeks for a total of two or three cycles. All except one patient with progressive disease underwent radical hysterectomy following neoadjuvant chemotherapy. Postoperative radiotherapy was given to the whole pelvis to 6 patients; 3 of the 6 patients with involved common iliac nodes received radiotherapy to a paraaortic field in addition to the whole pelvis.Results. Among 11 eligible patients, 7 had a partial response (64%). Stable disease was observed in 3 cases (27%) and progressive disease in 1 (9%). Histopathological changes related to chemotherapy, however, revealed only mild effects. Of the 24 treatment cycles administered, no Grade 3 or 4 toxicity was observed and there were no therapy-related deaths. The median follow-up period was 30 months (range, 1–65 months). The mean survival period was 34.7 months and the 5-year survival rate was 21.2%.Conclusions. Intraarterial neoadjuvant chemotherapy effectively reduced tumor size in patients with locally advanced cervical adenocarcinoma; however, a survival advantage was not clear.Gynecologic Oncology.
Article: High-Risk Group in Node-Positive Patients with Stage IB, IIA, and IIB Cervical Carcinoma after Radical Hysterectomy and Postoperative Pelvic Irradiation[show abstract] [hide abstract]
ABSTRACT: Objective. The goal of this study was to identify risk factors in patients with node-positive stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy with pelvic lymph node dissection and postoperative irradiation.Methods. Two hundred forty-two patients with FIGO stage IB, IIA, and IIB cervical carcinoma underwent radical hysterectomy with pelvic lymph node dissection; pathological analysis of the surgical specimen showed positive lymph nodes in 59 patients. These 59 patients were further treated with postoperative radiotherapy. Eighteen patients were in stage IB, 4 in stage IIA, and 37 in stage IIB. Histological tumor type, tumor size, lymph-vascular space invasion, parametrium infiltration, number of positive nodes, and involvement of common iliac nodes were assessed for correlation with cancer recurrence.Results. When all these variables were assessed in the Cox proportional regression analysis, parametrium infiltration (P = 0.0199) and number of positive nodes (two or more nodes) (P = 0.0483) revealed the factor correlating significantly with disease-specific survival. Based on these two factors, node-positive patients could be divided into low-risk (n = 11), intermediate-risk (n = 29), and high-risk (n = 19) groups. The 5-year disease-specific survival for the low-risk group was 100% which was significantly better than the 39.1% for the high-risk group (P = 0.0012).Conclusion. For patients in the high-risk group, it may be worthwhile to consider new strategies to improve survival.Gynecologic Oncology.